Tailor-made molecules for your applications
(0 item) - CHF0.00

You have no items in your shopping cart.

Spirochem opens new state-of-the-art Services and R&D facilities in Basel, Switzerland and Strengthens Board of Directors

spirochem_blog

 

Spirochem opens new state-of-the-art Services and R&D facilities in Basel, Switzerland and Strengthens Board of Directors

29 September 2017 - SpiroChem AG (“SpiroChem” or the “Company”), the Swiss fine chemicals company specialised in creating novel building blocks for use in drug discovery by its pharma and biotech partners, has today announced the relocation of its business to state-of-the-art facilities in Basel, Switzerland. The Company has also strengthened the Board with the appointment of Dr. Anthony Baxter to the Board of Directors with immediate effect.

With a growing reputation as a trusted partner of choice in the life sciences industry and increasing demand for SpiroChem’s innovative products, the Company has relocated to new, enlarged facilities in the Rosental Area of Basel. Previously the Company was based at world-renowned ETH Zürich. This relocation is an exciting step for the Company as it provides an ideal location for SpiroChem to significantly expand its operations and foster collaborations with existing and new customers and partners. The laboratories and team are now fully operational in Basel.

Dr Anthony Baxter joins the Company from Cyprotex plc, a leading supplier of DMPK services to the pharma and biotech community, where he held the position of CEO before its acquisition by Evotec AG in 2016 (£55m). Prior to this, Tony was the founding CEO of Argenta Discovery Ltd, a leading drug discovery services, and proprietary therapeutics company. In addition, Dr Baxter was CSO of Oxford Asymmetry International plc and helped build the business from an early stage company, to its flotation on the London Stock Exchange, and then to its eventual merger with Evotec AG in 2000 (£316m). Tony graduated from the University of Manchester in Salford, UK (MSc, PhD). Following this, Tony worked as a medicinal chemist with over 12 years senior level experience at GSK and Ciba-Geigy UK (now Novartis).

Thomas Fessard, CEO of SpiroChem, commented:

“We are excited to announce our move to state-of-the-art facilities in Basel. Our new set-up is ideal for interaction and collaborations with large and small organisations, providing flexibility and speed to solve problems, allowing our clients to focus on effectively designing the drugs of tomorrow. We will continue crafting innovative solutions for problems encountered in challenging and complex projects in the medicinal chemistry field. SpiroChem intends to become a key player in Basel’s vibrant, innovation-driven, life science scene, supporting our ambition to increase our portfolio of clients and recruit talented employees to join our growing, cutting-edge Company.

Working with Tony will be a real boost. His industry experience and network will be invaluable as we continue to grow our portfolio of small, medium, and large pharmaceutical, agrochemical and life science clients worldwide.”

Dr Baxter, Director, added:

“I am delighted to join the Board of SpiroChem as the Company enters the next key phase of development on the road towards becoming a leading innovation and drug discovery partner to the pharmaceutical industry. I very much look forward to working with the team and leveraging my industry knowledge and experience as a chemist to SpiroChem’s full advantage.”

Contacts

SpiroChem AG  - Tel: +41 61 685 95 00
Thomas Fessard, CEO

FTI Consulting  - Tel: +44 20 3727 1000
Mo Noonan / Anna Foster

________________

SpiroChem AG is a Swiss Fine Chemical Company founded in 2011 as an ETH-Zürich spin-off (group of Prof. Erick Carreira). SpiroChem has established itself as a world-leader in the field of novel building blocks for drug discovery and the expert on bioisosteric switch strategies. We have a broad portfolio of clients across the biotech and pharmaceutical industry as well as world-leading fine chemical companies.

SpiroChem drives the new molecule and synthesis innovation process, leading the way to new classes of molecules with highly attractive cost/benefit profiles due their intrinsic properties: 1) improved physico-chemical and pharmaco-kinetic properties and 2) chemical novelty allowing the generation of new intellectual property. The beneficial properties of SpiroChem’s compounds mean that our clients can optimize their drug candidates faster, therefore accelerating their drug discovery programs.

With recognized excellence in drug design and proprietary process chemistry technologies, SpiroChem efforts have been recognized with several entrepreneurial awards. It is the recipient of two sizable Swiss government grants (KTI). The forward-thinking initiatives enable discovery and innovation within the framework of research collaborations with ETH-Zürich.

Explore a new world of possibilities for innovation and discovery.